Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Genmab A/S (NASDAQ:GMABGet Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.20.

Several research firms recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. BMO Capital Markets restated an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th.

Get Our Latest Analysis on GMAB

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Genmab A/S by 123.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after buying an additional 1,787 shares during the period. Blue Trust Inc. increased its holdings in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the period. Headlands Technologies LLC lifted its stake in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Up 1.6 %

GMAB stock opened at $21.50 on Monday. The stock has a 50-day simple moving average of $22.64 and a two-hundred day simple moving average of $25.63. Genmab A/S has a twelve month low of $20.34 and a twelve month high of $32.88. The firm has a market capitalization of $14.23 billion, a PE ratio of 20.87, a PEG ratio of 0.65 and a beta of 0.99.

Genmab A/S (NASDAQ:GMABGet Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the firm posted $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.3 EPS for the current fiscal year.

Genmab A/S Company Profile

(Get Free Report

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Articles

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.